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In this issue of Cancer Cell, Cao and colleagues identify an FGF4/Jagged1-driven crosstalk between tumor
cells and their vascular niche that activates Notch signaling, sustaining the aggressiveness of certain mouse
and human B cell lymphomas. These findings identify new therapeutic opportunities to target pathogenic
angiocrine functions in cancer.TheNotch signaling pathway plays impor-
tant roles in development, tissue homeo-
stasis, and cancer. In mammals, Notch
signaling is mediated by four Notch
receptors (Notch1–4) interacting with
ligands of the Delta-like (Dll1, Dll3, and
Dll4) or Jagged (Jagged1 and Jagged2)
families. During physiological signaling,
ligand binding leads to intramembrane
receptor proteolysis and release of intra-
cellular Notch, which translocates to the
nucleus and initiates target gene tran-
scription. In cancer, activating NOTCH1
mutations were initially identified in a
majority of T cell acute lymphoblastic
leukemias (Figure 1A) (Weng et al.,
2004). A first class of point mutations in
the extracellular heterodimerization do-
main disrupts stability of a negative regu-
latory region, leading to constitutive
Notch activation even in the absence of
ligand. A second type of mutations trun-
cates the C-terminal PEST domain, lead-
ing to decreased proteasomal degrada-
tion and increased half-life of activated
Notch. Although first associated with
transformation of the T cell lineage, acti-
vating NOTCH mutations were subse-
quently identified in several subtypes of
B cell malignancies, including chronic
lymphocytic leukemia, mantle cell lym-
phoma, splenic marginal zone lymphoma,
and diffuse large B cell lymphoma
(Figure 1A) (Kiel et al., 2012; Kridel et al.,
2012; Lee et al., 2009; Martı´nez-Trillos
et al., 2013; Rossi et al., 2013). In almost
all of these cases, point mutations were
identified only within the region encod-
ing the PEST degron domain of either
NOTCH1 or NOTCH2, suggesting sen-
sitization to ligand-mediated receptor
activation rather than true constitutivesignaling. Moreover, systematic immu-
nohistochemical scoring demonstrates
NOTCH1 activation at a frequency that
markedly exceeds the reported preva-
lence of NOTCH1 mutations in specific
lymphoid malignancies, suggesting that
other mechanisms must exist to activate
Notch signaling in these diseases (Kluk
et al., 2013).
Results presented by Cao et al. (2014)
in this issue of Cancer Cell identify the
capacity of endothelial cells within the tu-
mor microenvironment to induce ligand-
mediated Notch activation in adjacent
lymphoma cells, leading to enhanced
tumor growth and aggressive in vivo
behavior (Figure 1B). Using complemen-
tary in vitro and in vivo models of mouse
and human Myc-driven lymphoma inter-
acting with a vascular niche, the authors
describe reciprocal interactions involving
FGF4-dependent induction of the ex-
pression of the Notch ligand Jagged1
in endothelial cells, leading in turn to
Notch2-mediated signaling in tumor cells
with lymphoma-initiating characteristics.
As a first step, Cao et al. (2014) built
on past work from their laboratory using
E4ORF1-transduced endothelial cells,
which can be maintained in culture
without serum or recombinant angiogenic
factors and allow for detailed analysis of
their angiocrine functions (Butler et al.,
2010). Co-culture of these endothelial
cells with Em-Myc-driven mouse B lym-
phoma cells selected for cells with
increased in vitro growth, chemoresist-
ance, in vivo repopulation potential, and
invasiveness. Using a combination of
genetic and pharmacological methods,
the authors demonstrated that this phe-
nomenon required Jagged1 expressionCancer Cell 2by the endothelial cells and Notch2, but
not Notch1, expression in lymphoma
cells. FGF4 release by the lymphoma
cells induced Jagged1 expression, sug-
gesting that specific lymphomas capable
of FGF4 production might be uniquely
sensitive to this mechanism (although
alternative pathwaysmight exist to induce
Jagged1). The effects of Notch2 ap-
peared entirely dependent on the Notch
target gene Hey1, while mechanisms
operating downstream of this transcrip-
tional repressor remain to be investigated.
To gain insight about the potential human
relevance of these findings, Cao et al.
(2014) analyzed a panel of primary human
Burkitt’s lymphomas, demonstrating the
existence of HEY1-positive cancer cells
in proximity of JAGGED1-expressing
endothelial cells in these tumors. More-
over, knockdown of NOTCH2 in these
primary human tumor cells followed by
transfer into immunodeficient mouse
recipients recapitulated observations
made with Em-Myc mouse tumors,
suggesting the existence of shared path-
ogenic mechanisms at least in these
Myc-driven lymphoid malignancies.
It remains to be determined how
broadly applicable the specific obser-
vations presented in this paper will be.
Of note, tumor-vasculature interactions
involving Notch signaling were reported
recently in other contexts, such as glio-
blastoma multiforme and colorectal can-
cer. An interesting implication of these
findings is that Notch activation might be
at play in malignant tissues even in the
absence of activating NOTCH mutations,
provided the tumor microenvironment
constitutes a good source of Notch
ligands. In lymphoid malignancies, PEST5, March 17, 2014 ª2014 Elsevier Inc. 261
Figure 1. Emerging Roles of Notch in Lymphoma Pathogenesis
(A) Structure of Notch1 and Notch2 receptors with sites of activating mutations previously reported in
lymphoid malignancies. T-ALL, T cell acute lymphoblastic leukemia/lymphoma; CLL, chronic lymphocytic
leukemia; MCL, mantle cell lymphoma; SMZL, splenic marginal zone lymphoma; ICN, intracellular Notch;
HD, heterodimerization domain; TMD, transmembrane domain.
(B) Proposed model for crosstalk between lymphoma cells (LC) and endothelial cells (EC), with Jagged1/
Notch2-driven effects on lymphoma aggressiveness (Cao et al., 2014). FGFR1, fibroblast growth factor
receptor 1; FGF4, fibroblast growth factor 4; ICN, intracellular Notch.
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only upon exposure of the tumor cells to
Notch ligands, because these genetic
events lead to stabilization of cleaved
active Notch only after ligand-receptor
interaction. Thus, PEST domain muta-
tions may function as a sensitizer for
the exposure of malignant cells to Notch
ligands in their immediate environment.
In other words, the type of ligand-depen-
dent mechanisms identified by Cao et al.
(2014) could synergize with PEST domain
Notch mutants to potently activate the
pathway. In terms of the overall impor-
tance of Notch as an oncogenic pathway
in B cell neoplasms, another word of
caution is that Notch signaling can have
versatile functions. Tumor suppressive
effects of the pathway have been re-
ported, for example, in myeloid neo-262 Cancer Cell 25, March 17, 2014 ª2014 Eplasms, squamous cell carcinomas, and
certain B cell malignancies (Zweidler-
McKay et al., 2005). It is possible that
Notch activation could have different
effects in lymphomas originating from
cells arrested at specific stages of
differentiation, such as before, during, or
after the germinal center reaction. To fully
investigate the spectrum of Notch effects
in lymphoma, future work should ideally
focus on in vivomodels and the combined
use of loss-of-function and gain-of-func-
tion experimental approaches.
The vascular niche represents an attrac-
tive potential source of Notch ligands
in the tumor microenvironment. In lym-
phoma, past observations revealed
increased Notch activity in a high propor-
tion of aggressive and highly vascularized
angioimmunoblastic T cell lymphomaslsevier Inc.(Kluk et al., 2013). However, other cellular
sources of Notch ligands must be con-
sideredaswell. Using standardized immu-
nohistochemistry to specifically detect
the cleaved and active form of NOTCH1
in tumor tissues, Aster and colleagues re-
ported evidence of high Notch activity
within secondary lymphoid organs, but
with rapid loss of the signal in tumor areas
that extend beyond the lymph node
capsule (Kluk et al., 2013). Although anec-
dotal, these findings suggest that cellular
elements specific to the lymph node
microenvironment might represent an
important source of Notch ligands in vivo.
Moving forward, additional work may
reveal specific mechanisms for Notch
ligand induction in this context and coop-
erativity with genetic Notch activation,
perhaps leading to the maintenance of
lymphoma-initiating cells in vivo. As a
practical implication, future investigations
are predicted to underestimate or to
altogether miss the importance of Notch
signaling in lymphoid malignancies if
tumor cells are not adequately exposed
to Notch ligands in culture (e.g., in the
absence of cocultured cells expressing
relevant Notch ligands) or in vivo (e.g., in
conventional subcutaneous xenografts).
The translational impact of the findings
reported by Cao et al. (2014) is significant,
because they imply a larger array of
potential tumor targets for the use
of therapeutic Notch inhibition than pre-
dicted only by NOTCH mutational anal-
ysis. Therefore, emerging data implicating
a central role for Notch ligands derived
from the tumor vasculature or other
sources suggest that our current
understanding of Notch in lymphoma-
genesis has only exposed the tip of the
iceberg. It is time to dive deeper.REFERENCES
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Individual cancer cells can exhibit striking differences in tumorigenic potential following experimental
transplantation, but themolecular pathways that regulate this activity remain poorly understood. In this issue
of Cancer Cell, Blackburn and colleagues report that Akt signaling regulates both leukemia-propagating
potential and proliferation rate via distinct pathways in T-ALL.Cancers arise as clonal outgrowths from
individual transformed cells, but the
resultant population of tumor cells often
harbors extensive phenotypic variability.
Of particular interest is the observation
that different cells of an individual
cancer can exhibit marked differences
in disease-propagating activity following
transplantation into unaffected reci-
pients, suggesting fundamental differ-
ences in their tumorigenic properties.
One model to explain these differences
is the cancer stem cell model, which
posits that a subpopulation of cancer
cells harbors a tumor’s disease-propa-
gating potential, and this cancer stem
cell population gives rise to a ‘‘bulk’’
cancer cell population that lacks tumor-
propagating potential. This model is
well supported by experimental evidence
in several tumor types, including acute
myeloid leukemia (Lapidot et al., 1994),
but equally convincing evidence argues
against this model in other tumors such
as melanoma (Quintana et al., 2008).
Independent of the cancer stem cell
model, genetic mutations, epigenetic
alterations, and/or environmental influ-
ences, can give rise to distinct tumor
subclones with extensive functionalvariation within the disease-propagating
population.
Limiting-dilution transplantation exper-
iments to assess tumor-propagating
potential have emerged as a promising
experimental tool to interrogate func-
tional variability among tumor cell popu-
lations. In this issue of Cancer Cell,
Blackburn and colleagues began their
investigation of phenotypic variegation
in T cell acute lymphoblastic leukemia
(T-ALL) leukemia-propagating cells
(LPC) using the limiting-dilution trans-
plantation assay in a zebrafish model of
Myc-induced T-ALL (Blackburn et al.,
2014). In this transplantation tour-de-
force, 16 fluorescently labeled primary
T-ALLs were subjected to serial limiting-
dilution transplantation into syngeneic
recipients (n = 6,024 transplantations) to
assess the evolution of LPC frequency
and time to T-ALL onset (latency) in
distinct subclones derived from a com-
mon ancestral progenitor.
The authors show that, although the
LPC frequency of individual clones is rela-
tively stable following serial transplanta-
tion, most primary T-ALLs (81%) harbor
clones with functional heterogeneity, as
evidenced by variations in latency andLPC frequency. Importantly, they demon-
strate that LPC frequency can be un-
coupled from leukemic growth rate and
disease latency, arguing that the path-
ways that control tumor latency versus
LPC potential can evolve independently.
The authors then investigated potential
molecular mechanisms involved and
found that evolution of increasing LPC
frequency was associated with Akt
pathway activation. Expression of con-
stitutively active Akt cooperated with
transgenic Myc or intracellular (constitu-
tively active) notch1a to accelerate leuke-
mia onset and increase LPC frequency,
implicating Akt signaling as a key regu-
lator of these phenotypes.
The authors then investigated the con-
tribution of two key pathways down-
stream of Akt to these phenotypes:
Gsk3b-dependent inhibition of Myc
degradation and Tsc-dependent activa-
tion of Rheb, which is best known as a
positive regulator of mammalian target
of rapamycin complex 1 (mTorc1) activity.
Surprisingly, expression of constitutively
active Rheb increased LPC frequency
without accelerating tumor onset. By
contrast, expression of a Myc T58A
mutant that is resistant to proteasomal5, March 17, 2014 ª2014 Elsevier Inc. 263
